• Plk1 Control of p31comet in Checkpoint Disassembly

  2026-10-05

  The 2019 PNAS study identifies Polo-like kinase 1 (Plk1) as a negative regulator of p31comet-mediated mitotic checkpoint complex disassembly. Its central finding is that Plk1 phosphorylation of p31comet at S102 restrains the TRIP13–p31comet pathway, helping prevent premature or futile cycling of checkpoint assembly and disassembly during mitosis.

• MK-0893: Evidence for Glucagon Receptor Antagonism

  2026-10-05

  The reference study describes the discovery and optimization of MK-0893, a potent and selective glucagon receptor antagonist that inhibits receptor-linked cAMP signaling. Its activity in human glucagon receptor models, diabetic mice, and rhesus monkeys supported advancement into further preclinical and clinical evaluation, while also defining important limits on interpretation and translation.

• Paroxetine: Molecular Mechanisms and Evidence

  2026-10-03

  Kowalska and colleagues provide an integrative review of paroxetine that connects its canonical serotonin-transporter action with pharmacokinetic, kinase, receptor, and viral-glycoprotein interactions. The paper’s main practical value is interpretive: it shows why paroxetine should be evaluated as a multi-target molecule while keeping clinical relevance, off-target pharmacology, and evidence limitations distinct.

• From CAML Phenotypes to NLRP3 Mechanism

  2026-10-02

  A translational framework for using NBC19 to connect circulating cancer-associated macrophage-like cell biology with NLRP3-driven IL-1β signaling, while preserving the distinction between phenotypic association, mechanistic evidence, and clinical relevance.

• TH287 MTH1 Inhibitor: Practical Assay Guide

  2026-10-01

  This scenario-driven guide explains how TH287 MTH1 inhibitor, SKU B5849, can improve the interpretation and design of cancer-cell viability, DNA-damage, and radiosensitization experiments. It integrates product handling data with recent CRPC evidence while separating documented findings from practical workflow recommendations.

• CD44-Copper Signaling in Ly6Chi Macrophages and UC

  2026-10-01

  A Cellular Signalling study identifies CD44-associated copper accumulation and impaired ATP7A export as a mechanism linked to Ly6Chi macrophage activation in ulcerative colitis. By combining single-cell analysis, proteomics, pharmacological intervention, antibody blockade, and macrophage experiments, the work connects metal handling with ROS-associated inflammatory pathology while leaving important questions about molecular causality and assay specificity open.

• TRPV1+ Nerves and the Somato-Autonomic Reflex

  2026-09-30

  Song et al. show that stimulating TRPV1+ peripheral afferents at the nape suppresses systemic inflammation through coordinated brainstem, endocrine, autonomic, and splenic responses. The study provides a mechanistic framework for region-specific neuroimmune intervention while identifying important limits for translating this reflex into other experimental systems.

• Bismuth Subsalicylate: A Mechanism-to-Assay Guide

  2026-09-30

  Explore how Bismuth Subsalicylate can support gastrointestinal disorder research through mechanism-aware study design and orthogonal membrane-state readouts. This guide connects prostaglandin G/H synthase inhibition with annexin V assay interpretation while emphasizing formulation, controls, and experimental limits.

• LNP Trafficking, Endosomal Entrapment, and Escape

  2026-09-29

  This study shows that efficient lipid nanoparticle delivery depends on intracellular routing, not simply on cellular uptake. Using sensitive LNP labeling and defined endolysosomal states, the authors identify peripheral endosome entrapment as a barrier to lysosomal-region trafficking and cytosolic cargo release.

• Live-Dead Cell Staining Kit for Biomaterials

  2026-09-29

  Use Calcein-AM and Propidium Iodide dual staining to separate metabolic activity from membrane failure in cytotoxicity, scaffold, and drug-delivery experiments. This practical workflow adapts the Live-Dead Cell Staining Kit to both fluorescence microscopy and flow cytometry while addressing hydrogel autofluorescence, dye stability, and apoptosis-related interpretation.

• QNZ (EVP4593) in NF-κB Research Workflows

  2026-09-28

  QNZ (EVP4593) provides a nanomolar small-molecule approach for probing NF-κB activation, TNF-α output, inflammation, and disease-relevant neuronal signaling. This workflow connects reporter assays with tissue-level measurements while separating established product findings from testable applications in osteomyelitis and Huntington’s disease research.

• Procainamide Hydrochloride in Translational Research

  2026-09-28

  Procainamide Hydrochloride is best understood as a multi-axis research tool: a cardiac sodium channel blocker with additional reported epigenetic and immunomodulatory activities. A pregnant-mouse cisplatin study offers a useful translational case study in how to test those findings carefully—without mistaking preclinical evidence for clinical guidance.

• PP 3 Controls for Translational Src Pathway Research

  2026-09-27

  A developmental vascular study shows why pathway conclusions depend on separating Src kinase activity from other routes linking NADPH oxidase-derived ROS to contraction. This article translates those findings into a practical control strategy for PP 2 experiments, including how PP 3 can strengthen interpretation without overstating what a negative control proves.

• Clozapine N-oxide for Chemogenetic Assays

  2026-09-26

  Clozapine N-oxide (CNO) is a practical actuator for DREADD-based neuronal activity modulation, but it should not be assumed to be biologically neutral in every assay. This workflow pairs chemogenetic controls with a published 24-hour 5-HT2 receptor study to help researchers distinguish engineered-receptor effects from broader cellular responses.

• TH287 MTH1 Inhibitor for CRPC Radiosensitization

  2026-09-25

  TH287 offers a practical way to test whether blocking oxidized-nucleotide repair can intensify radiation responses in castration-resistant prostate cancer cells. A CRPC study highlights treatment timing as a key variable, with radiation 12 hours after TH287 producing the strongest reported combination effect.

8558 records 1/571 page Next 12345 下5页 Last page